Insmed
INSM
674 hedge funds and large institutions have $35.7B invested in Insmed in 2026 Q1 according to their latest regulatory filings, with 101 funds opening new positions, 288 increasing their positions, 215 reducing their positions, and 95 closing their positions.
52% more call options, than puts
Call options by funds: $352M | Put options by funds: $232M
34% more repeat investments, than reductions
Existing positions increased: 288 | Existing positions reduced: 215
18% more funds holding in top 10
Funds holding in top 10: 22 → 26 (+4)
6% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 95
0.58% more ownership
Funds ownership: 101.92% → 102.5% (+0.58%)
0% less funds holding
Funds holding: 677 → 674 (-3)
6% less capital invested
Capital invested by funds: $37.8B → $35.7B (-$2.13B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$497M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$259M |
| 3 |
BlackRock
New York
|
+$248M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$209M |
| 5 |
D.E. Shaw & Co
New York
|
+$196M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$635M |
| 2 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$355M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$155M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$146M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$142M |
INSM Hedge Fund Activity: Q1 2026 in Review
674 institutional investors reported a position in Insmed (INSM) for Q1 2026, worth a combined $35.7B — down 5.6% from $37.8B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new INSM positions and 95 closed out — a net gain of 6 holders — while 288 added to existing stakes and 215 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $497M. The largest seller was Darwin Global Management, cutting an estimated $635M.
- 674 institutional investors held Insmed (INSM) as of Q1 2026, down from 677 in Q4 2025.
- Funds reported $35.7B of Insmed stock for Q1 2026, down 5.6% quarter-over-quarter.
- 101 funds opened new Insmed positions in Q1 2026 and 95 closed out, a net change of +6 holders.
- The largest Insmed buyer in Q1 2026 was Fidelity Investments, an estimated $497M added.
- The largest Insmed seller in Q1 2026 was Darwin Global Management, an estimated $635M sold.
Based on aggregated 13F filings for Q1 2026.